This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
CICC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
In a report released yesterday, from CICC maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$45.00. The company’s shares closed last Monday at HK$40.02.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of HK$40.23.
WXIBF market cap is currently HK$165.3B and has a P/E ratio of 35.88.
Read More on WXIBF:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
